The Experts below are selected from a list of 13044 Experts worldwide ranked by ideXlab platform
Christopher D. Hillyer - One of the best experts on this subject based on the ideXlab platform.
-
Minority donation in the United States: challenges and needs.
Current opinion in hematology, 2010Co-Authors: Beth H. Shaz, Christopher D. HillyerAbstract:Purpose of reviewIn the United States, blood donation rates of African–Americans are 25–50% of that of white individuals. As African–Americans make up an ever increasing and now Substantial Minority, and African–American recipients of blood transfusion, both specialized, such as sickle cell disease
Xavier Carné - One of the best experts on this subject based on the ideXlab platform.
-
Who is willing to participate in low-risk pragmatic clinical trials without consent?
European journal of clinical pharmacology, 2017Co-Authors: Rafael Dal-ré, Antonio J. Carcas, Xavier CarnéAbstract:Purpose General notification offers a possible alternative to written informed consent for pragmatic randomized controlled trials (pRCTs). It involves patients being informed through brochures, posters, and letters that research is being conducted simultaneously to providing clinical care and that patients will be enrolled in pRCTs without study-specific consent. A previous survey found that a Substantial Minority of respondents endorsed general notification. We aimed to know who is willing to enroll in this type of trials using general notification rather than written consent.
Megan Griffith - One of the best experts on this subject based on the ideXlab platform.
-
MENTOR heralds a new era of therapy for membranous nephropathy
Nature Reviews Nephrology, 2019Co-Authors: Aikaterini Nikolopoulou, Megan GriffithAbstract:The MENTOR trial reported that rituximab is superior to ciclosporin for remission of nephrotic syndrome in patients with membranous nephropathy. Rituximab is better tolerated than other treatments but, as up to 40% of patients did not respond to rituximab, alternative immunosuppressive therapies may still be required for a Substantial Minority of patients.
Ezekiel J Emanuel - One of the best experts on this subject based on the ideXlab platform.
-
patients views on financial conflicts of interest in cancer research trials
The New England Journal of Medicine, 2006Co-Authors: Lindsay A Hampson, Manish Agrawal, Steven Joffe, Cary P Gross, Joel Verter, Ezekiel J EmanuelAbstract:BACKGROUND Financial ties between researchers or medical centers and companies whose drugs are being tested have come under increasing scrutiny. METHODS We conducted in-person interviews with 253 patients in cancer-research trials (a 93% response rate) at five U.S. medical centers to determine their attitudes regarding potential financial conflicts of interest among researchers and medical centers. RESULTS More than 90% of patients expressed little or no worry about financial ties that researchers or institutions might have with drug companies. Most patients said they would have enrolled in the trial even if the drug company had paid the researcher for speaking (82% of those interviewed) or consulting (75%) or if the researcher had received royalty payments (70%) or owned stock in the company (76%). Similarly, most patients would have enrolled in the trial if their cancer center had owned stock in the drug company (77%) or received royalty payments from the company (79%). Most patients believed it was ethical for researchers to receive speaking fees (81%) or consulting fees (82%) from the company. However, a Substantial Minority of patients wanted disclosure of the oversight system for researchers (40%) and of researchers' financial interests (31%); 17% thought no disclosure to patients was necessary. CONCLUSIONS Most patients in cancer-research trials were not worried about financial ties between researchers or medical centers and drug companies and would still have enrolled in the trial if they had known about such financial ties. A Substantial Minority wanted to be informed about the oversight system to protect against financial conflicts of interest and about researchers' financial interests.
Enrica Morra - One of the best experts on this subject based on the ideXlab platform.
-
Delayed cytogenetic response with prolonged interferon-alpha treatment in chronic myeloid leukemia patients: quantification of BCR-ABL transcript by competitive reverse transcription-polymerase chain reaction.
Haematologica, 2001Co-Authors: Roberto A. Perego, Anna Maria Nosari, Giorgia Cornacchini, Cristina Bianchi, Matteo Corizzato, Enrica MorraAbstract:Interferon-a (IFN) induces a major reduction of the Philadelphia chromosome (Ph) positive clone in about 40% of patients with chronic myelogenous leukemia (CML) in chronic phase (CP) and in a Substantial Minority a complete cytogenetic response (CCyR), predicting a favorable outcome, 1,2 Most of the major CyR are obtained within one year from starting therapy; we present data concerning patients in whom late major and complete CyR were achieved after prolonged treatment with IFN.
